Terapia Genica e Cellulare

Laboratori 2021/2022 - Terapia Genica e Cellulare

Di seguito è possibile visionare l’elenco dei Directors of Studies (e i link ai rispettivi CV) e i progetti presentati per l' a.a. 2021/2022 all'interno del curriculum in Terapia Genica e Celllulare

7 BORSE A PROGETTO:

BORSA A PROGETTO GCT1: AIUTI ALESSANDRO

Unit: Pathogenesis and therapy of primary immunodeficiencies

GCT1: Characterization of Mucopolysaccharidosis Type IV murine models to develop pre-clinical gene therapy strategies

BORSA A PROGETTO GCT3: CITRO ANTONIO

Unit: Diabetes Research Institute – Pancreas Bioengineering

GCT3: Human Vascularized Islet Organ (hVIO) as an extracorporeal model for the study of physiopathology and drug screening in diabetes.

BORSA A PROGETTO GCT4: DI MICCO RAFFAELLA

Unit: Senescence in Stem Cell Aging Differentiation and Cancer

GCT4: Gaining insights on hematopoietic stem cell response to endogenous DNA damage to further advance gene and cell therapies

BORSA A PROGETTO GCT5: MORTELLARO ALESSANDRA

Unit: Pathogenesis and Therapy of Primary Immunodeficiencies

GCT5: Study of disease pathogenesis and development of gene therapy for adenosine deaminase 2 deficiency

BORSA A PROGETTO GCT6: LORENZO PIEMONTI

Unit: Diabetes Research Institute - Beta Cell Differentiation Unit

GCT6: Pre-clinical approaches of cell therapy for type 1 diabetes with induced pluripotent stem cell (iPSC) – derived β cells

BORSA A PROGETTO GCT7 (TBD): LORENZO PIEMONTI

Unit: Diabetes Research Institute - Beta Cell Biology Unit

GCT7: Vanguard: Bioartificial Pancreas to Cure Type 1 Diabetes

DI MICCO RAFFAELLA

Unit: Senescence in Stem Cell Aging Differentiation and Cancer

Identification and targeting of senescence programs during hematopoietic stem cell aging

GENTNER BERNHARD

Unit: Translational Stem Cell & Leukemia Research

New gene therapy approaches for leukemia

OSTUNI RENATO

Unit: Genomics of the innate immune system

Dissection and therapeutic exploitation of macrophage diversity